Reaffirms FY23 adjusted EBITDA view $5.0B-$5.4B.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on VTRS:
- Viatris Reports Strong Financial and Operational Results for the Third Quarter 2023 and Reaffirms Full-Year 2023 Adjusted EBITDA and Free Cash Flow Guidance Ranges[1]
- VTRS Earnings this Week: How Will it Perform?
- Theravance Biopharma, Teva enter into settlement agreement related to Yupelri
- Viatris downgraded to Underperform from Neutral at BofA
- Viatris price target lowered to $11 from $12 at UBS